iX Biopharma Ltd. engages in the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, as well as male erectile dysfunction. It operates through the following segments: Specialty Pharmaceutical, Chemical Analysis, and Nutraceutical. The Specialty Pharmaceutical segment manufactures and sells pharmaceutical products. The Chemical Analysis segment provides laboratory testing services. The Nutraceutical segment offers nutraceutical products. The company was founded by Lee Yip Hang on May 8, 2004 and is headquartered in Singapore.